Advertisement

Cell-Free DNA Analysis to Distinguish Development of Malignant Peripheral Nerve Sheath Tumors From Plexiform Neurofibromas


Advertisement
Get Permission

The inherited condition neurofibromatosis type 1, or NF1, is responsible for the development of benign tumors that grow along the nerves; in some individuals, however, these benign tumors transform into aggressive and malignant peripheral nerve sheath tumors. Determining whether this transformation has occurred is challenging. Researchers have developed a blood test that they believe could one day offer a highly sensitive and inexpensive approach to detect these cancers in people with NF1. Their findings were published by Szymanski et al in PLOS Medicine.

Study Background

NF1 is the most common cancer predisposition syndrome, affecting 1 in 3,000 people worldwide. The condition, caused by a mutation in the NF1 gene, is almost always diagnosed in childhood. Roughly half of people with NF1 will develop large but benign tumors on nerves, called plexiform neurofibromas. In up to 15% of people with plexiform neurofibromas, these benign tumors turn into malignant peripheral nerve sheath tumors (MPNST).

Patients with MPNST have a poor prognosis because the cancer can quickly spread and often becomes resistant to both chemotherapy and radiation. Among people diagnosed with MPNST, 80% die within 5 years.

“Imagine going through life with a cancer predisposition syndrome like NF1. It’s kind of like a ticking bomb,” said study coauthor Jack F. Shern, MD, a Lasker Clinical Research Scholar in the National Cancer Institute’s Pediatric Oncology Branch. “The doctors are going to be watching for cancerous tumors, and you’re going to be watching for them, but you really want to discover that transformation to cancer as early as possible.”

Doctors currently use either imaging scans or biopsies to determine if plexiform neurofibromas have transformed into MPNST. However, biopsy findings aren’t always accurate, and the procedure can be extremely painful for patients because the tumors grow along nerves. Imaging tests, meanwhile, are expensive and can also be inaccurate.

“What we don't have right now is a tool to help us determine if within that big, bulky benign plexiform neurofibroma, something bad is cooking and it's turning into an MPNST,” Dr. Shern said. “So we thought, ‘What if we developed a simple blood test where instead of a … scan, we could just draw a tube of blood and say whether or not the patient has an MPNST somewhere?’”

KEY POINTS

  • Patients with MPNST had pieces of cell-free DNA that were shorter than those in people with plexiform neurofibromas or without NF1.
  • The plasma tumor fraction in the blood samples was much higher in people with MPNST than in those with plexiform neurofibromas.
  • In the study participants with MPNST, the plasma tumor fraction also aligned with how well they responded to treatment.

Cell-Free DNA Analysis

In pursuit of this goal, the research team collected blood samples from 23 people with plexiform neurofibromas, 14 patients with MPNST that had not yet been treated, and 16 healthy people without NF1. Most of the study participants were adolescents and young adults, the age group in which MPNST most often develops. The researchers isolated cell-free DNA from the blood samples and used whole-genome sequencing technology to look for differences in the genetic material among the three groups.

The cell-free DNA in patients with MPNST had several features that distinguished it from the DNA in the other two groups. For example, patients with MPNST had pieces of cell-free DNA that were shorter than those in people with plexiform neurofibromas or without NF1. In addition, the proportion of cell-free DNA that comes from tumors—called the “plasma tumor fraction”—in the blood samples was much higher in people with MPNST than in those with plexiform neurofibromas. Together, these differences allowed the researchers to differentiate, with 86% accuracy, between patients with plexiform neurofibromas and those with MPNST.

In the study participants with MPNST, the plasma tumor fraction also aligned with how well they responded to treatment. In other words, if their plasma tumor fraction decreased following treatment, the size and number of their tumors (as measured by imaging scans) also decreased. An increase in plasma tumor fraction was associated with metastatic recurrence.

“You can imagine treating a patient with a chemotherapy regimen. This blood test could easily and rapidly allow us to determine whether the disease is going down or maybe even going away entirely,” Dr. Shern said. “And if you had done surgery and taken out an MPNST, and the blood test was negative, you could use that to monitor the patient going forward to see if the tumor returns.”

Dr. Shern noted that one limitation of the current study is its small size, even though it included people with NF1 from two large hospitals. The researchers are planning to conduct a larger trial with more patients. Dr. Shern said the team’s goal is to increase the accuracy of the blood test from 86% to closer to 100%. One approach would be to refine the genetic analysis to focus on genes known to be involved in MPNST.

A simple and inexpensive blood test to detect MPNST early in NF1 patients would be especially useful in developing countries and other resource-poor areas, where access to the equipment and expertise needed to perform imaging is limited, Dr. Shern said.

Blood tests of this type also have applications in the early detection and monitoring of patients with other cancer-predisposing genetic disorders, such as multiple endocrine neoplasia or Li-Fraumeni syndrome.

“This is the perfect opportunity to apply these technologies where we can use a simple blood test to screen an at-risk population,” said Dr. Shern. “If the test shows something abnormal, that’s when we know to act and go looking for a tumor.”

Disclosure: The study was supported by the Intramural Research Program of the National Cancer Institute and the National Institute of General Medical Sciences. For full disclosures of the study authors, visit journals.plos.org.

The content in this post has not been reviewed by the American Society of Clinical Oncology, Inc. (ASCO®) and does not necessarily reflect the ideas and opinions of ASCO®.
Advertisement

Advertisement



Advertisement